Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
Following treatment with DNMTI therapy, patients with MDS have differences in survival according to the quality of their treatment response. In this analysis, patients who achieve CRh had similar OS compared to those meeting standard “CR” criteria, which was better than the survival of those with ot...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-022-00748-9 |
| _version_ | 1811217690263552000 |
|---|---|
| author | Andrew M. Brunner Alexander Gavralidis Najla Al Ali Anthony Hunter Rami Komrokji Amer Zeidan David A. Sallman |
| author_facet | Andrew M. Brunner Alexander Gavralidis Najla Al Ali Anthony Hunter Rami Komrokji Amer Zeidan David A. Sallman |
| author_sort | Andrew M. Brunner |
| collection | DOAJ |
| description | Following treatment with DNMTI therapy, patients with MDS have differences in survival according to the quality of their treatment response. In this analysis, patients who achieve CRh had similar OS compared to those meeting standard “CR” criteria, which was better than the survival of those with other treatment responses (p < 0.0001). |
| first_indexed | 2024-04-12T06:58:58Z |
| format | Article |
| id | doaj.art-383dd7c757d94ef89eb58a9a3c7829dc |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-04-12T06:58:58Z |
| publishDate | 2022-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-383dd7c757d94ef89eb58a9a3c7829dc2022-12-22T03:43:03ZengNature Publishing GroupBlood Cancer Journal2044-53852022-11-0112111610.1038/s41408-022-00748-9Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)Andrew M. Brunner0Alexander Gavralidis1Najla Al Ali2Anthony Hunter3Rami Komrokji4Amer Zeidan5David A. Sallman6Massachusetts General Hospital Cancer CenterNorth Shore Medical CenterMoffitt Cancer CenterEmory UniversityMoffitt Cancer CenterYale University School of MedicineMoffitt Cancer CenterFollowing treatment with DNMTI therapy, patients with MDS have differences in survival according to the quality of their treatment response. In this analysis, patients who achieve CRh had similar OS compared to those meeting standard “CR” criteria, which was better than the survival of those with other treatment responses (p < 0.0001).https://doi.org/10.1038/s41408-022-00748-9 |
| spellingShingle | Andrew M. Brunner Alexander Gavralidis Najla Al Ali Anthony Hunter Rami Komrokji Amer Zeidan David A. Sallman Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) Blood Cancer Journal |
| title | Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) |
| title_full | Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) |
| title_fullStr | Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) |
| title_full_unstemmed | Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) |
| title_short | Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) |
| title_sort | evaluating complete remission with partial hematologic recovery crh as a response criterion in myelodysplastic syndromes mds |
| url | https://doi.org/10.1038/s41408-022-00748-9 |
| work_keys_str_mv | AT andrewmbrunner evaluatingcompleteremissionwithpartialhematologicrecoverycrhasaresponsecriterioninmyelodysplasticsyndromesmds AT alexandergavralidis evaluatingcompleteremissionwithpartialhematologicrecoverycrhasaresponsecriterioninmyelodysplasticsyndromesmds AT najlaalali evaluatingcompleteremissionwithpartialhematologicrecoverycrhasaresponsecriterioninmyelodysplasticsyndromesmds AT anthonyhunter evaluatingcompleteremissionwithpartialhematologicrecoverycrhasaresponsecriterioninmyelodysplasticsyndromesmds AT ramikomrokji evaluatingcompleteremissionwithpartialhematologicrecoverycrhasaresponsecriterioninmyelodysplasticsyndromesmds AT amerzeidan evaluatingcompleteremissionwithpartialhematologicrecoverycrhasaresponsecriterioninmyelodysplasticsyndromesmds AT davidasallman evaluatingcompleteremissionwithpartialhematologicrecoverycrhasaresponsecriterioninmyelodysplasticsyndromesmds |